



THE UNIVERSITY *of* EDINBURGH

Edinburgh Research Explorer

Developing defined substrates for stem cell culture and differentiation

Citation for published version:

Hagbard, L, Cameron, K, August, P, Penton, C, Parmar, M, Hay, D & Kallur, T 2018, 'Developing defined substrates for stem cell culture and differentiation', *Philosophical Transactions of the Royal Society B: Biological Sciences*. <https://doi.org/10.1098/rstb.2017.0230>

Digital Object Identifier (DOI):

[10.1098/rstb.2017.0230](https://doi.org/10.1098/rstb.2017.0230)

Link:

[Link to publication record in Edinburgh Research Explorer](#)

Document Version:

Peer reviewed version

Published In:

Philosophical Transactions of the Royal Society B: Biological Sciences

General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.



**Developing defined substrates for stem cell culture and
differentiation**

Journal:	<i>Philosophical Transactions B</i>
Manuscript ID	RSTB-2017-0230.R1
Article Type:	Review
Date Submitted by the Author:	26-Mar-2018
Complete List of Authors:	Hagbard, Louise; BioLamina Cameron, Kate; University of Edinburgh August, Paul; Icagen Inc Penton, Christopher; Icagen Inc Parmar, Malin; Lund University Hay, David; University of Edinburgh, Kallur, Therese; BioLamina,
Issue Code (this should have already been entered but please contact the Editorial Office if it is not present):	TISSUE
Subject:	Cellular Biology < BIOLOGY, Biotechnology < BIOLOGY, Developmental biology < BIOLOGY
Keywords:	Defined substrates, human recombinant laminin, human pluripotent stem cells, cell culture, cell therapy

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

TITLE

Developing defined substrates for stem cell culture and differentiation

AUTHORS

Louise Hagbard¹, Katherine Cameron², Paul August³, Christopher Penton³, Malin Parmar⁴, David C. Hay² and Therése Kallur¹

AFFILIATIONS

¹BioLamina, Löfströms Allé 5A, 172 66 Sundbyberg, Sweden

²Medical Research Council Centre for Regenerative Medicine, University of Edinburgh, 5 Little France Drive, Edinburgh, EH16 4UU, United Kingdom

³Icagen, Discovery Biology, Tucson Innovation Center, Oro Valley, AZ 85755, USA

⁴Wallenberg Neuroscience Center, Department of Experimental Medical Science, Lund University, 221 84 Lund, Sweden

CONTACT DETAILS

Therése Kallur

Email: therese.kallur@biolamina.com

Correspondence: BioLamina, Löfströms Allé 5A, 172 66 Sundbyberg, Sweden

RUNNING TITLE

Laminins for primary cell culture

SUMMARY

Over the past few decades, a variety of different reagents for stem cell maintenance and differentiation have been commercialized. These reagents share a common goal in facilitating the manufacture of products suitable for cell therapy whilst reducing the amount of non-defined components. Lessons from developmental biology have identified signalling molecules that can guide the differentiation process *in vitro*, but less attention has been paid to the extra-cellular matrix used. With the introduction of more biologically relevant and defined matrices, that better mimic specific cell niches, researchers now have powerful resources to fine-tune their *in vitro* differentiation systems, that may allow the manufacture of therapeutically relevant cell types. In this review article, we revisit the basics of the extracellular matrix, and explore the important role of the cell-matrix interaction. We focus on laminin proteins since they help to maintain pluripotency and drive cell fate specification.

Keywords:

Defined substrates, human recombinant laminins, human pluripotent stem cells, cell culture, cell therapy

INTRODUCTION

Following the derivation of human embryonic stem cells (hESC) in 1998¹, and with the development of human induced pluripotent stem cells (hiPSC) in 2007^{2,3}, stem cell research is rapidly progressing from preclinical studies to the clinical arena with first in-human trials already begun. Continued growth in the cell therapy industry and the commercialization of cell therapies has led to an increased awareness for the need of specialized and defined materials.

Current practices for the maintenance and expansion of undifferentiated human pluripotent stem cells (hPSCs) typically depend on the support of undefined culture systems, such as feeder cells (often mouse embryonic fibroblasts) or undefined basement membrane (BM) extracts such as MatrigelTM and Geltrex[®] containing laminin-111, entactin, collagen, heparin sulfate proteoglycans and growth factors purified from Engelbreth-Holm-Swarm mouse sarcoma. Besides the risk of transmitting pathogens and the introduction of tumor-derived growth factors, culture conditions that depend on these undefined support systems limit experimental reproducibility and the ability to interpret mechanistic studies due to lot-to-lot variations. Ultimately, they hinder the transition of hPSC-derived products into a clinical setting.

Over the past decade, several feeder-free, extracellular matrix (ECM) protein culture matrices have appeared on the market that are defined and xeno-free⁴⁻⁶. However, not all ECM proteins are suitable for hPSC culture since they cannot maintain an undifferentiated⁷ or allow clonal survival of hPSCs without the use of apoptosis inhibitors or undefined additives⁸. Moreover, hPSCs were often passaged as clumps on these substrates, which significantly induced the risk of spontaneous differentiation⁸. High production costs, labour intensive cell passaging and the limited

scale-up potential associated with many of these ECM substrates have driven researchers to seek alternative substrates in the synthetic polymer arena. For example, SynthemaxTM, an acrylate surface with deposits of various peptide-polymer conjugates, has been developed for the adhesion and expansion of hESC⁹. Synthetic scaffolds composed of poly(desaminotyrosyl tyrosine ethyl ester carbonate)¹⁰, a tyrosine derived polycarbonate polymer¹¹, have also been utilised to study the effects of geometry on hESC survival and self-renewal. Carlson *et al.* have shown that poly-D-lysine pre-treated scaffolds support hESC survival and colony formation. However, the authors also illustrated the importance of cell-ECM interactions for cell functionality and concluded that the endogenous cell production of laminin was an essential factor for adhesion and survival of the hESCs¹⁰.

A lack of biologically relevant signals from the matrix increases the risk for mixed cell populations and genetic and phenotypic drift *in vitro*. Compared to many other feeder-free matrices on the market, full-length laminin-521 better mimics the natural environment for hPSCs in culture^{7, 8, 19}. Due to their biologically relevant interactions with cells, laminin-based substrates have significantly advanced the stem cell research field and are therefore the focus of this article. Over the last decade, laminins have become a preferred cell culture substrate both within basic research as well as for researches and companies with a therapeutic focus⁴⁵.

THE EXTRACELLULAR MATRIX AND THE IMPORTANCE OF BIOLOGICAL RELEVANCE FOR CELL CULTURE

Most organized and stationary cells of the body grow on specialized, sheet-like ECM structures called basement membranes (BM). Different cells and tissues require a specific ECM composition for survival and proper function¹², and many cells, such as

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

fibroblasts¹³, endothelial cells¹⁴ and cardiomyocytes¹⁵, themselves produce and deposit ECM proteins. The BM contains specific, highly conserved proteins, and consists mostly of laminin, type IV collagen, agrin, perlecan, fibronectin and nidogen^{12, 16} (Figure 1a).

Over the past 40 years, several adhesion molecules (fibronectin, vitronectin, laminin-111, or a placenta-derived mixture of laminins) have been discovered and used to improve cell cultures^{17, 18}. The concept of adhesive matrix molecules has gradually improved: adhesion is not only for anchoring cells in place but is also crucial for cell survival and phenotype maintenance. Cells which lack their relevant ECM cues undergo anoikis, controlled suicide, which is a natural mechanism that allows for the correct organization of tissues and for the selection of specific cell types. Laminin and type IV collagen form networks that have a structural role, influence cell migration and regulate the differentiation processes of associated cells. Nidogens are sulfated glycoproteins that link the BM proteins together, and the glycosaminoglycan-containing perlecan and agrin bind growth factors and contribute to the matrix volume¹⁹. Laminins are the most abundant component of the BM. In addition to their structural functions, laminins play an essential role in the structural organization of the BM and the regulation of cell behaviour²⁰.

Laminins are multidomain, heterotrimeric glycoproteins, composed of three different subunits; an α -chain, β -chain and γ -chain, combined and expressed in at least 16 different isoforms in the human body^{16, 19}. The physical, topological, and biochemical expression of the different laminin isoforms in the BM is heterogeneous and laminin expression changes during development. Laminin-111 is widely expressed during embryogenesis, but its tissue distribution after birth is restricted to only a few tissues, such as the brain and kidney²¹. After birth, the α 5-laminins are

most common²². Without the right combination of laminin isoforms cells and tissues becomes dysfunctional. While epithelial cells need laminin-332 together with laminin -511/521 for proper function, muscle and nerve cells require laminin -211, -221 and laminin -511/521, and endothelial cells prefer a combination of laminin -411/421 and laminin -511/521¹⁹.

The molecular structure of laminins is cross-shaped with the N-terminal ends forming three short arms, containing globular laminin N-terminal domains and a globular laminin IV domain^{23, 24}. Each of these domains are separated by rod-like, epidermal-growth-factor-like domains, harbouring nidogen binding sites²⁵. Nidogen and perlecan in turn, allow the laminin network to be connected to collagen IV. The globular N-terminal domains also bind to syndecans which regulate cell adhesion and motility^{26, 27} (Figure 1b). Cells bind to laminins via cell-surface receptors, such as integrins, which regulate vital cellular responses, such as proliferation and differentiation, migration, phenotype stability, and resistance to apoptosis^{19, 28, 29}. The $\alpha 5$ -laminins (especially laminin -511 and laminin -521) exhibit the broadest degree of integrin binding interactions²². There are many binding sites on the full-length laminin molecule which can interact with cell membrane receptors, however, the molecular mechanism underlying the laminin-mediated signalling to integrins and other cell surface receptors is still not fully elucidated. Studies indicate that the LG domains in C-terminal region of laminins are highly involved in laminin recognition by integrins^{30, 31}. Integrins, α -dystroglycan, perlecan and sulphated glycolipids also interact with some of the globular N-terminal laminin domains^{16, 32}. Fractionated laminin molecules isolated from tissue and truncated laminin molecule derivatives lack most of the laminin domains that are required for the formation of a proper extracellular network. Moreover, full-length recombinant laminins with all their

native biological activities intact are essential for biomimetic *in vitro* function³³ and for the stimulation of authentic cellular signal transductions. Emphasizing biology and mimicking the natural matrix proteins is one of the most important aspects to create a biologically relevant milieu for the cells, resulting in phenotypically stable cell cultures and reproducible protocols.

**BIOLOGICALLY RELEVANT CELL CULTURE MATRICES ENABLE
CLINICAL TRANSLATION OF RESEARCH PROTOCOLS**

Advancing a PSC-derived cell therapy from pre-clinical studies to a Phase 1 clinical trial requires a demonstration of a well-controlled production process and a safe and efficacious product to the regulatory agencies. The development of a differentiation protocol that generates the target cell type at a sufficient quantity and purity, with phenotypic maturity and appropriate cellular functions is arguably challenging. Due to their validated functionality and biological properties, human recombinant laminins in conjunction with streamlined differentiation protocols, offer exciting prospects for regenerative medicine. This has been highlighted in a number of high-impact scientific articles in the past two years and a few examples are described below:

Pluripotent stem cell derivation, maintenance and safety

In the developing embryo, laminins containing the α 1- and α 5-chain are the first ECM proteins to be expressed. They are essential for early embryogenesis and initiation of morphogenesis²⁰. α 5-chain laminins (i.e. laminin-521 and laminin-511) are produced by and surround the cells in the inner cell mass of the blastocyst which gives rise to all embryonic tissues^{12, 19, 34} (Figure 1c). α 5 laminin is also produced endogenously by pluripotent hPSCs cultured *in vitro* and is a critical autocrine and paracrine factor that regulates hPSC survival and self-renewal. Knockdown and disruption of the *LAMA5*

gene dramatically reduces hPSC self-renewal and increases apoptosis⁷. LN-521 thus constitutes the relevant niche for pluripotent stem cells when cultured *in vitro*. Laminin-111 is mostly expressed in the Reichert's membrane, which supports the outer extra-embryonic layer of trophoblasts and is widely expressed during embryogenesis^{12, 35} (Figure 1d). Hence, using cell culture substrates that contain laminin-111 (e.g. Matrigel or Cultrex) is suboptimal for reliable survival and expansion of hESCs and hiPSCs^{8, 19, 28}. Human ESCs dissociated into single-cell suspension and plated on Matrigel, or different human recombinant laminin (LN) substrates, LN-111, LN-121, LN-511 and LN-521, in the presence of apoptosis inhibitor (ROCK inhibitor, Y-27632), survive on all surfaces. However, in the absence of ROCK inhibitor, hESCs do not survive well on Matrigel, LN-111 or LN-121, whereas they readily adhere and spread on LN-511 and LN-521⁸. By culturing cells on the laminin isoforms that they normally adhere to *in vivo in vitro*, the biologically relevant niche is better recapitulated by the medium and the matrix.

In 2014, Rodin *et al.* first described an efficient xeno-free and chemically defined protocol for monolayer culturing of hPSC on LN-521³⁶ (Figure 2a). Via the interaction to specific hPSC cellular receptors, LN-521 triggers authentic cell signalling pathways, which promotes high survival (Figure 2b) and robust long-term expansion of single-cell cultured hESC and hiPSC (Figure 2c), even without the addition of ROCK inhibitor or any other inhibitors of anoikis. LN-521 binds to $\beta 1$ integrin receptors, primarily $\alpha 6\beta 1$, which plays a pivotal role in the stem cell-matrix interaction. Human PSCs predominantly express the $\alpha 6\beta 1$ integrin, which interacts strongly with LN-521 globular domains inducing the PI3K/Akt pathway^{8, 37, 38}. The inactivation of focal adhesion kinase (FAK) signalling pathway via the $\alpha 6\beta 1$ integrin is also linked the hPSC self-renewal and expression of pluripotency³⁹. The motility of

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

hPSCs on LN-521 is higher than that of the cells on other matrices, which correlates to the high survival of the cells⁸.

Human PSCs in single-cell suspension plated on LN-521 quickly attach, migrate and form monolayer colonies which rapidly expand (Figure 2a). Human PSCs cultured in thick multilayer colonies often require manual, arbitrary removal of spontaneously differentiated parts. In contrast, hPSCs cultured on LN-521 grow as a homogenous monolayer, with minimal risk of spontaneous differentiation or genetic abnormalities⁴⁰. The biologically relevant culture environment generates hPSC cultures with a more uniform gene expression between different hPSC lines⁴¹ and enhances cell maturation, polarization and functional organization in many cell applications^{42, 43, 44}.

The LN-521 matrix also allows efficient clonal derivation, clonal survival and long-term self-renewal of hESCs. Human ESC lines can even be derived from a single blastomere under chemically defined and xeno-free conditions^{8, 45}, which circumvents the ethical issues associated with embryo destruction for hESC line derivation. The biologically relevant culture environment provided by the LN-521 substrate allows for flexible culture protocols that support weekend-free feeding⁴⁰, ultra-low seeding density (>5,000 cells/cm²) and high confluence culture.

Stem cell derived dopamine progenitors from a high-yield GMP-adapted differentiation protocol

Parkinson’s disease (PD) is an interesting target for cell replacement therapies due to its focal degeneration of midbrain dopamine (DA) neurons. Proof-of-concept has been achieved in clinical trials using human foetal ventral mesencephalic (VM) tissue⁴⁶. However, the low availability of such tissue limits its use, and a renewable

1
2
3 source of cells is required in order to develop a therapy that is accessible to a large
4
5 number of patients.
6

7 A new differentiation protocol that efficiently and rapidly patterns hESCs to
8
9 midbrain DA neurons using extrinsic patterning agents has been developed in recent
10
11 years^{47, 48}. These stem cell derived DA neurons function *en par* with fetal midbrain
12
13 DA neurons⁴⁹. Kirkeby *et al.* have developed a fully defined and xeno-free protocol.
14
15 Even so, a number of steps were required to develop a Good Manufacturing Practice
16
17 (GMP) version compliant with use in clinical trials^{44, 50}. One important step was to
18
19 switch from an initial suspension culture step to a fully attached protocol. Matrigel
20
21 had previously been used for this purpose³² but is not ideal for GMP manufacturing
22
23 and more suitable substrates, such as recombinant laminins were required for GMP
24
25 production.
26
27

28
29 Seven different recombinant laminin isoforms were screened for their ability
30
31 to replace Matrigel/free floating suspension cultures and 4 of them were found to
32
33 efficiently support adherent differentiation of VM progenitors (LN-111, LN-421, LN-
34
35 511 and LN-521). It has previously been reported that LN-511 and LN-521 efficiently
36
37 support growth of hPSCs⁸, making them less ideal in this differentiation protocol. In
38
39 contrast, undifferentiated hESCs detach from LN-111-coated culture dishes when
40
41 kept in pluripotency medium but efficiently attach in neural differentiation medium
42
43 making it an ideal substrate to move forward with.
44
45

46 When implementing this in the GMP protocol, the differentiation on LN-111
47
48 resulted in robust and reproducible differentiation of midbrain DA progenitors with
49
50 minimal variation between batches^{44, 50}. Moreover, the yield was >40 times higher
51
52 than the original research grade differentiation protocol^{44, 48} (Figure 3a). This high
53
54 yield means that it is possible to produce >3.8 x 10⁸ transplantable progenitor cells in
55
56
57
58
59
60

16 days when starting from just 1×10^6 undifferentiated hESCs⁴⁴ (Figure 3b). This would provide more than 500 doses of cryopreserved DA neurons from one manual manufacturing batch at a relatively small scale.

Recombinant laminins support the differentiation potential of satellite cell-derived myoblasts during long-term culture

Every tissue in the body originates from a stem cell during development but there are a number of tissues where stem cells exist to facilitate tissue regeneration in the adult. In skeletal muscle, that stem cell is called the satellite cell and it remains quiescent unless stimulated by muscle damage⁵¹. Upon damage, it enters a program to asymmetrically expand to generate a transit amplifying cell and another satellite cell⁵²,⁵³. The transit amplifying cell undergoes several rounds of division to create a population of cells called myoblasts that can fuse together to create new muscle fibers or fuse to existing fibers to repair membrane lesions.

Large-scale expansion of muscle stem cells *in vitro* is critical for a variety of purposes. Large quantities of satellite cells are required for cell engineering, cell therapy and to support skeletal muscle drug discovery campaigns. Relatively small numbers of primary satellite cells must be scalable to millions, even billions of cells, while maintaining the ability to differentiate into mature myotubes. While multiple substrates have been commonly used for growth of satellite cells, long term effects of culturing on different substrates has not been well characterized. Matrigel is commonly utilized, however, it is a complex substrate exhibiting significant lot-to-lot variation, and variable amounts of growth factors that may skew experimental outcomes and mitigates reliable translation of protocols from the literature to drug discovery applications⁵⁴. Additionally, Matrigel implementation varies largely from lab to lab making it difficult to reliably translate protocols from the literature for drug

discovery applications. In order to develop an optimized and defined culture platform, an in-depth comparison of long-term satellite cell activity between multiple defined extracellular matrices and Matrigel has been performed. It was shown that LN-521 dramatically enhances the proliferation and differentiation of satellite cells and extends their culture potential well past previously established passaging limits⁴³. Following eight passages *in vitro*, LN-521 expanded satellite cells form more mature myotubes containing high numbers of nuclei and better organization compared to the other substrates (Figure 3c). In contrast, both LN-111 and Matrigel expanded cultures contain smaller immature myotubes with small numbers of nuclei (Figure 3d), an effect observed with both human and mouse derived satellite cells. Overall, it was demonstrated that LN-521 provides a good substrate that enables large-scale expansion in a shorter time while maintaining a differentiation performance that better resembles freshly isolated cells⁴³.

Additional work from Penton and colleagues has demonstrated that cells grown on LN-521 show enhanced engraftment into skeletal muscle niches *in vivo* (unpublished). Although there have been many publications that suggest the limited utility of satellite cells for cell therapy, those experiments may have been flawed since they employed satellite cells that had already lost some of their expansion and differentiation potential *in vitro*. Interestingly, satellite cell markers including pax7 and integrin alpha 7 were expressed at similar levels across substrates suggesting that LN-521 is regulating satellite cell activity through novel mechanisms (unpublished). Plating satellite cells on LN-521 immediately after isolation by fluorescence activated cell sorting (FACS) appears to fundamentally protect the cells from the loss of the expansion and differentiation abilities. Penton and colleagues are investigating

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

additional approaches that should permit enhanced expansion and engraftment to develop advanced therapeutic approaches for patients with muscular dystrophies.

Previous studies have shown that transplanted hPSC-derived myogenic cells can fuse with host myofibers and improve muscle function⁵⁵. However, it is unknown if hPSC-derived myotubes alone can generate 3D functional skeletal muscle since comparison studies suggest they are more developmentally immature than primary myotubes. By trying to mimic the tissue architecture both with biologically relevant matrix molecules and different 3D approaches, it is possible to generate functional biomimetic skeletal muscle tissues entirely from hPSC-derived myogenic cells⁵⁶.

Recombinant laminins drive the differentiation and self-organization of hESC-derived hepatocytes

There has been tremendous progress over the last 15 years in generating pure populations of endodermal cells, including hepatocytes, for biomedical application⁵⁷. While cell-based models improve the ability to model human liver biology ‘in the dish’ and may be suitable for cell-based therapy, most approaches rely on undefined materials in the differentiation process⁵⁸. This severely limits technology reproducibility and scale up, acting as a barrier to technology translation.

In recent years, serum free and chemically defined differentiation procedures have been developed⁵⁹ that have been validated by the pharmaceutical industry to be as good as their current gold standard⁶⁰. While this marked progress at the time, the early prototype systems still relied on poorly defined ECMs, such as Matrigel, which resulted in batch-to-batch variation. Since these studies, a differentiation system has been designed using polymer library screening to identify new polyurethane substrates for cell culture^{61, 62}.

More recently, differentiation has been performed using recombinant laminins⁴². This enabled a highly reproducible and transformative differentiation process, which has been semi-automated to permit large scale manufacture. Importantly, cells generated in this manner express proteins, HNF4a, MRP1 and albumin, found in hepatocyte (Figure 3e and f). An essential part of the stem cell scale-up is the ability to use highly defined ‘off the shelf reagents’.

FROM HERE TO THE FUTURE: ENABLING CELL THERAPY

Pluripotent stem cells, whether they are derived from human embryos or reprogrammed adult or foetal somatic cells, have an intrinsic capability for unlimited self-renewal and the ability to make all the cells in the body. They are therefore an ideal candidate to be used as starting material for cell therapies. Much effort has been put into creating methods for hPSC expansion that are defined, robust, simple and safe⁶³. Having a defined method ensures low variance, high-quality, traceability and control over reagents, all required for manufacture of clinical grade cells. The robustness of the method allows consistency of results and predictability. A simple and controlled method reduces cost, minimizes the risk for mistakes, and will more likely be adapted by users. Ultimately, the most important aspect of the hPSC culture method is to create a safe cell source. With extended time in culture, cells may begin to drift genetically, resulting in chromosomal abnormalities. Although hPSCs have an impressive ability to maintain genomic integrity over time, chromosomal abnormalities often occur at higher passages and/or as a result of suboptimal culture conditions^{40, 64, 65}.

Cell therapy grade cell culture substrates

The stem cell therapy field is still in its infancy. Translational researchers are now looking more intensely at the quality and character of both the cell products and the culture products used for primary, stem and differentiated cells. So far, FDA and EMA have not demanded GMP for phase 1 studies but it is evident that the methods employed today will not be sustainable for commercial therapies. As a consequence, the conversion of optimized, scalable, and standardized culture methods into GMP-compatible protocols will become another challenge. Each and every reagent needs to be high quality, traceable, controlled and preferably manufactured according to GMP. To address these issues a cell therapy grade (CTG) LN-521 substrate has been developed to enable cell therapy fast forward to an affordable price. The CTG LN-521 substrate is stably expressed and produced by CAP[®]Go cell, a suspension-based platform already used for therapeutic proteins in human clinical trials, and is a validated source of protein of ethically accepted origin. A qualified GMP master cell bank (MCB) together with a scalable and regulatory compliant production process of CTG LN-521, serve as the foundation for translational research and cell manufacture.

Cell culture at the appropriate scale and with automation

Generation of hESC and hiPSC lines is laborious. To decrease the amount of work needed, increase success rates and minimize hazardous deviations, the process needs to be standardized. In addition, an automated process is desirable to avoid subjective, operator-dependent mistakes and to cut costs.

Generally, upscaling is achieved by manual expansion in traditional culture vessels or through scalable planar flask cultures, which all involve multi-layered stacked-plate systems. Automation of traditional culture vessels, such as plates and flasks, can be achieved by pipetting (semi or whole) closed system robotics. Another

approach is packed-bed bioreactors which are perfusion-based 3D scaffolds. A further type of bioreactor supported system offering the precise control of the culture environment is microcarrier culture in stirred tanks, ideal systems for achieving required lot sizes. The surface-area-to-volume is greatly increased and thus renders more cells with less medium, reagents and materials⁶⁶.

Stem cell scale-up and subsequent differentiation would ideally be performed in the same, closed, automated and fully controlled bioreactor. Human recombinant laminin can easily be adsorbed by microcarriers (e.g. Corning® Enhanced Attachment Microcarriers) and LN-521 coated microcarriers have been shown to sustain expansion of both hESC and hiPSCs in stirred tank bioreactors, with sequential differentiation to cardiomyocytes⁶⁷ (Figure 2d).

Importance of biological relevance: spatial, temporal and regional impact

The development of robust protocols that safely and accurately direct hESC and hiPSC into the desired cell types, mimicking the signalling that occurs during development is difficult to achieve *in vitro*. While many protocols successfully recapitulate the temporal developmental processes via well designed medium formulations, the majority of protocols ignore the role of the ECM and the spatial and tissue specific distribution of the ECM proteins that form the tissue architecture.

One of the biggest and most obvious differences between cells cultured in 2D versus 3D is their morphology. The orientation of the integrin mediated adhesions, guides the orientation and thus the shape of the cells. A 3D microenvironment influences the attachment, spreading, growth, and most importantly cell polarity^{68, 69}. The limitations of 2D cultures have contributed to poor predictive power of pre-clinical cell-based drug and toxicity screening assays. Human recombinant laminins,

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

in combination with other key ECM molecules, can be used together with various available 3D solutions. Hydrogels can be covalently linked with proteins and thus serve as a 3D context for the cells. In addition, recombinant silk proteins can be used as scaffolds that can easily be adsorbed with e.g. LN-521 to maintain and differentiate hESCs towards different lineages. In order to mirror the correct *in vivo* tissue assembly *ex vivo*, and to regenerate damage tissue and even repair whole body parts, biologically relevant and physiological matrices in a structure allowing spatial orientation need to be developed.

This article has been designed to create an awareness around the necessity and need for defined materials to improve basic scientific research and to permit the translation of these advances through reliable manufacture of cell-based products at a large scale. Additionally, we emphasize the importance of a close collaboration between the users, suppliers and regulators to facilitate the commercial development of safe and effective cell therapies globally.

COMPETING INTERESTS

LH and TK are both employed by BioLamina AB and PA and CP by Icagen Inc. DCH is a founder, director and shareholder in Stemnovate Limited. DCH is also a director and shareholder in HigherSteaks Limited.

ACKNOWLEDGEMENTS

DCH and KC were funded by the UKRMP MR/K026666/1 and MR/ L022974/1. BioLamina received support from the Eurostars-2 Joint Programme with co-funding from the European Union's Horizon 2020 research and innovation programme and the Swedish Governmental Agency for Innovation Systems (2014-04086). MP is a New York Stem Cell Foundation Robertson investigator.

For Review Only

REFERENCES

1. Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, Jones JM. 1998 Embryonic stem cell lines derived from human blastocysts. *Science*. Nov 06;282(5391):1145-7.

2. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, Nie J, Jonsdottir GA, Ruotti V, Stewart R, et al. 2007 Induced pluripotent stem cell lines derived from human somatic cells. *Science*. Dec 21;318(5858):1917-20. DOI: 10.1126/science.1151526

3. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S. 2007 Induction of pluripotent stem cells from adult human fibroblasts by defined factors. *Cell*. Nov 30;131(5):861-72. DOI: 10.1016/j.cell.2007.11.019

4. Braam SR, Zeinstra L, Litjens S, Ward-van Oostwaard D, van den Brink S, van Laake L, Lebrin F, Kats P, Hochstenbach R, et al. 2008 Recombinant vitronectin is a functionally defined substrate that supports human embryonic stem cell self-renewal via $\alpha 5 \beta 1$ integrin. *Stem Cells*. 26:2257–2265.

5. Nagaoka M, Si-Tayeb K, Akaike T, Duncan SA. 2010 Culture of human pluripotent stem cells using completely defined conditions on a recombinant E-cadherin substratum. *BMC Dev Biol*. 10:60.

6. Miyazaki T, Futaki S, Suemori H, Taniguchi Y, Yamada M, Kawasaki M, Hayashi M, Kumagai H, Nakatsuji N, Sekiguchi K, et al. 2012 Laminin E8 fragments support efficient adhesion and expansion of dissociated human pluripotent stem cells. *Nat Commun*. 3:1236

7. Laperle A, Hsiao C, Lampe M, Mortier J, Saha K, Palecek SP, Masters KS. 2015 $\alpha 5$ Laminin Synthesized by Human Pluripotent Stem Cells Promotes Self-Renewal. *Stem Cell Reports*. Aug 11;5(2):195-206. DOI: 10.1016/j.stemcr.2015.06.009

8. Rodin S, Antonsson L, Niaudet C, Simonson OE, Salmela E, Hansson EM, Domogatskaya A, Xiao Z, Damdimopoulou P, Sheikhi M, et al. 2014 Clonal culturing of human embryonic stem cells on laminin-521/E-cadherin matrix in defined and xeno-free environment. *Nat Comms*. 5:3195. DOI: 10.1038/ncomms41959.

9. Melkounian Z, Weber JL, Weber DM, Fadeev AG, Zhou Y, Dolley-Sonneville P, Yang J, Qiu L, Priest CA, Shogbon C, Martin AW, et al. 2010 Synthetic peptide-acrylate surfaces for long-term self-renewal and cardiomyocyte differentiation of human embryonic stem cells. *Nat Biotechnol*. 28:606–610.

10. Carlson AL, Florek CA, Kim JJ, Neubauer T, Moore JC, Cohen RI, Kohn J, Grumet M, Moghe PV. 2012 Microfibrous substrate geometry as a critical trigger for organization, self-renewal, and differentiation of human embryonic stem cells within synthetic 3-dimensional microenvironments. *FASEB J*. 26:3240–3251.

11. Meechaisue C, Dubin R, Supaphol P, Hoven VP, Kohn J. 2006 Electrospun mat of tyrosine-derived polycarbonate fibers for potential use as tissue scaffolding material. *J Biomater Sci Polym Ed*. 17:1039–1056.

12. Miner JH, Yurchenco PD. 2004 Laminin functions in tissue morphogenesis. *Annu Rev Cell Dev Biol*. 20:255-84. DOI:10.1146/annurev.cellbio.20.010403.094555

13. Hongisto H, Vuoristo S, Mikhailova A, Suuronen R, Virtanen I, Otonkoski T, Skottman H. 2012 Laminin-511 expression is associated with the functionality of feeder cells in human embryonic stem cell culture. *Stem Cell Res*. Jan;8(1):97-108. doi: 10.1016/j.scr.2011.08.005. Epub 2011 Aug 27.

14. Nikolova G, Jabs N, Konstantinova I, Domogatskaya A, Tryggvason K, Sorokin L, Fässler R, Gu G, Gerber HP, Ferrara N, et al. 2006 The vascular basement membrane: a niche for insulin gene expression and Beta cell proliferation. *Dev Cell*. Mar;10(3):397-405.
15. Bowers SL1, Banerjee I, Baudino TA. 2010 The extracellular matrix: at the center of it all. *J Mol Cell Cardiol*. Mar;48(3):474-82. doi: 10.1016/j.yjmcc.2009.08.024. Epub 2009 Aug 31.
16. Yurchenco PD. 2011 Basement membranes: cell scaffoldings and signaling platforms. *Cold Spring Harb Perspect Biol*. Feb 01;3(2). DOI: 10.1101/cshperspect.a004911
17. Klebe RJ. 1974 Isolation of a collagen-dependent cell attachment factor. *Nature*. Jul 19;250(463):248-51.
18. Timpl R, Rohde H, Robey PG, Rennard SI, Foidart JM, Martin GR. 1979 Laminin--a glycoprotein from basement membranes. *J Biol Chem*. Oct 10;254(19):9933-7.
19. Domogatskaya A, Rodin S, Tryggvason K. 2012 Functional diversity of laminins. *Annu Rev Cell Dev Biol*. 28:523-53. DOI: 10.1146/annurev-cellbio-101011-155750
20. Diaz de la Loza MC, Diaz-Torres A, Zurita F, Rosales-Nieves AE, Moeendarbary E, Franze K, Martín-Bermudo MD, González-Reyes A. 2017 Laminin Levels Regulate Tissue Migration and Anterior-Posterior Polarity during Egg Morphogenesis in *Drosophila*. *Cell Rep*. Jul 05;20(1):211-23. DOI: 10.1016/j.celrep.2017.06.031
21. Yurchenco PD. 2015 Integrating Activities of Laminins that Drive Basement Membrane Assembly and Function. *Curr Top Membr*. 76:1-30. DOI: 10.1016/bs.ctm.2015.05.001
22. Miner JH, Lewis RM, Sanes JR. 1995 Molecular cloning of a novel laminin chain, alpha 5, and widespread expression in adult mouse tissues. *J Biol Chem*. Dec 01;270(48):28523-6.
23. Hussain SA, Carafoli F, Hohenester E. 2011 Determinants of laminin polymerization revealed by the structure of the alpha5 chain amino-terminal region. *EMBO Rep*. Mar;12(3):276-82. DOI: 10.1038/embor.2011.3
24. Carafoli F, Hussain SA, Hohenester E. 2012 Crystal structures of the network-forming short-arm tips of the laminin beta1 and gamma1 chains. *PLoS One*. 7(7):e42473. DOI: 10.1371/journal.pone.0042473
25. Stetefeld J, Mayer U, Timpl R, Huber R. 1996 Crystal structure of three consecutive laminin-type epidermal growth factor-like (LE) modules of laminin gamma1 chain harboring the nidogen binding site. *J Mol Biol*. Apr 05;257(3):644-57. DOI: 10.1006/jmbi.1996.0191
26. Okamoto O, Bachy S, Odenthal U, Bernaud J, Rigal D, Lortat-Jacob H, Smyth N, Rousselle P. 2003 Normal human keratinocytes bind to the alpha3LG4/5 domain of unprocessed laminin-5 through the receptor syndecan-1. *J Biol Chem*. Nov 07;278(45):44168-77. DOI: 10.1074/jbc.M300726200
27. Ogawa T, Tsubota Y, Hashimoto J, Kariya Y, Miyazaki K. 2007 The short arm of laminin gamma2 chain of laminin-5 (laminin-332) binds syndecan-1 and regulates cellular adhesion and migration by suppressing phosphorylation of integrin beta4 chain. *Mol Biol Cell*. May;18(5):1621-33. DOI: 10.1091/mbc.E06-09-0806

28. Fiore A, Spencer VA, Mori H, Carvalho HF, Bissell MJ, Bruni-Cardoso A. 2017 Laminin-111 and the Level of Nuclear Actin Regulate Epithelial Quiescence via Exportin-6. *Cell Rep.* Jun 06;19(10):2102-15. DOI: 10.1016/j.celrep.2017.05.050
29. Reilly GC, Engler AJ. 2010 Intrinsic extracellular matrix properties regulate stem cell differentiation. *J Biomech.* Jan 05;43(1):55-62. DOI: 10.1039/C0SM00339E
30. Deutzmann R, Aumailley M, Wiedemann H, Pysny W, Timpl R, Edgar D. 1990 Cell adhesion, spreading and neurite stimulation by laminin fragment E8 depends on maintenance of secondary and tertiary structure in its rod and globular domain. *Eur J Biochem.* Jul 31;191(2):513-22.
31. Sung U, O'Rear JJ, Yurchenco PD. 1993 Cell and heparin binding in the distal long arm of laminin: identification of active and cryptic sites with recombinant and hybrid glycoprotein. *J Cell Biol.* Dec;123(5):1255-68.
32. Aumailley M, Bruckner-Tuderman L, Carter WG, Deutzmann R, Edgar D, Ekblom P, Engel J, Engvall E, Hohenester E, Jones JC, et al. 2005 A simplified laminin nomenclature. *Matrix Biol.* Aug;24(5):326-32. DOI: 10.1016/j.matbio.2005.05.006
33. Gjorevski N, Sachs N, Manfrin A, Giger S, Bragina ME, Ordonez-Moran P, Clevers H, Lutolf MP. 2016 Designer matrices for intestinal stem cell and organoid culture. *Nature.* Nov 24;539(7630):560-4. DOI: 10.1038/nature20168
34. Ekblom P, Lonai P, Talts JF. 2003 Expression and biological role of laminin-1. *Matrix Biol.* Mar;22(1):35-47.
35. Klaffky E, Williams R, Yao CC, Ziober B, Kramer R, Sutherland A. 2001 Trophoblast-specific expression and function of the integrin alpha 7 subunit in the peri-implantation mouse embryo. *Dev Biol.* Nov 01;239(1):161-75. DOI: 10.1006/dbio.2001.0404
36. Rodin S, Antonsson L, Hovatta O, Tryggvason K. 2014 Monolayer culturing and cloning of human pluripotent stem cells on laminin-521-based matrices under xeno-free and chemically defined conditions. *Nat Protoc.* Oct;9(10):2354-68. DOI: 10.1038/nprot.2014.159
37. Rodin S, Domogatskaya A, Strom S, Hansson EM, Chien KR, Inzunza J, Hovatta O, Tryggvason K. 2010 Long-term self-renewal of human pluripotent stem cells on human recombinant laminin-511. *Nat Biotechnol.* Jun;28(6):611-5. DOI: 10.1038/nbt.1620
38. Miyazaki T, Futaki S, Hasegawa K, Kawasaki M, Sanzen N, Hayashi M, Kawase E, Sekiguchi K, Nakatsuji N, Suemori H. 2008 Recombinant human laminin isoforms can support the undifferentiated growth of human embryonic stem cells. *Biochem Biophys Res Commun.* Oct 10;375(1):27-32. DOI: 10.1016/j.bbrc.2008.07.111
39. Villa-Diaz LG, Kim JK, Laperle A, Palecek SP, Krebsbach PH. 2015 Inhibition of Focal Adhesion Kinase Signaling by Integrin alpha6beta1 Supports Human Pluripotent Stem Cell Self-Renewal. *Stem Cells.* Jul;34(7):1753-64. DOI: 10.1002/stem.2349
40. Jacobs K, Zambelli F, Mertzanidou A, Smolders I, Geens M, Nguyen HT, Barbé L, Sermon K, Spits C. 2016 Higher-Density Culture in Human Embryonic Stem Cells Results in DNA Damage and Genome Instability. *Stem Cell Reports.* Mar 08;6(3):330-41. DOI: 10.1016/j.stemcr.2016.01.015
41. Albalushi H, Kurek M, Karlsson L, Landreh L, Kjartansdóttir KR, Söder O, Hovatta O, Stukenborg JB. 2018 Laminin 521 Stabilizes the Pluripotency Expression Pattern of Human Embryonic Stem Cells Initially Derived on Feeder Cells. *Stem Cells Int.* Feb 18;2018:7127042. doi: 10.1155/2018/7127042.

42. Cameron K, Tan R, Schmidt-Heck W, Campos G, Lyall MJ, Wang Y, Lucendo-Villarin B, Szkolnicka D, Bates N, Kimber SJ, et al. 2015 Recombinant Laminins Drive the Differentiation and Self-Organization of hESC-Derived Hepatocytes. *Stem Cell Reports*. Dec 08;5(6):1250-62. DOI: 10.1016/j.stemcr.2015.10.016
43. Penton CM, Badarinarayana V, Prisco J, Powers E, Pincus M, Allen RE, August PR. 2016 Laminin 521 maintains differentiation potential of mouse and human satellite cell-derived myoblasts during long-term culture expansion. *Skelet Muscle*. Dec 13;6(1):44. DOI: 10.1186/s13395-016-0116-4
44. Kirkeby A, Nolbrant S, Tiklova K, Heuer A, Kee N, Cardoso T, Ottosson DR, Lelos MJ, Rifés P, Dunnett SB, et al. 2017 Predictive Markers Guide Differentiation to Improve Graft Outcome in Clinical Translation of hESC-Based Therapy for Parkinson's Disease. *Cell Stem Cell*. Jan 05;20(1):135-48. DOI: 10.1016/j.stem.2016.09.004
45. Hovatta O, Rodin S, Antonsson L, Tryggvason K. 2014 Concise review: animal substance-free human embryonic stem cells aiming at clinical applications. *Stem Cells Transl Med*. Nov;3(11):1269-74. DOI: 10.5966/sctm.2014-0129
46. Barker RA, Drouin-Ouellet J, Parmar M. 2015 Cell-based therapies for Parkinson disease-past insights and future potential. *Nat Rev Neurol*. Sep;11(9):492-503. DOI: 10.1038/nrneurol.2015.123
47. Kriks S, Shim JW, Piao J, Ganat YM, Wakeman DR, Xie Z, Carrillo-Reid L, Auyeung G, Antonacci C, Buch A, et al. 2011 Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease. *Nature*. Nov 06;480(7378):547-51. DOI: 10.1038/nature10648
48. Kirkeby A, Grealish S, Wolf DA, Nelander J, Wood J, Lundblad M, Lindvall O, Parmar M. 2012 Generation of regionally specified neural progenitors and functional neurons from human embryonic stem cells under defined conditions. *Cell Rep*. Jun 28;1(6):703-14. DOI: 10.1016/j.celrep.2012.04.009
49. Grealish S, Diguët E, Kirkeby A, Mattsson B, Heuer A, Bramoulle Y, Van Camp N, Perrier AL, Hantraye P, Björklund A, et al. 2014 Human ESC-derived dopamine neurons show similar preclinical efficacy and potency to fetal neurons when grafted in a rat model of Parkinson's disease. *Cell Stem Cell*. Nov 06;15(5):653-65. DOI: 10.1016/j.stem.2014.09.017
50. Nolbrant S, Heuer A, Parmar M, Kirkeby A. 2017 Generation of high-purity human ventral midbrain dopaminergic progenitors for in vitro maturation and intracerebral transplantation. *Nat Protoc*. Sep;12(9):1962-79. DOI: 10.1038/nprot.2017.078
51. Zammit PS, Partridge TA, Yablonka-Reuveni Z. 2006 The skeletal muscle satellite cell: the stem cell that came in from the cold. *J Histochem Cytochem*. Nov;54(11):1177-91. DOI: 10.1369/jhc.6R6995.2006
52. Cooper RN, Tajbakhsh S, Mouly V, Cossu G, Buckingham M, Butler-Browne GS. 1999 In vivo satellite cell activation via Myf5 and MyoD in regenerating mouse skeletal muscle. *J Cell Sci*. Sep;112 (Pt 17):2895-901.
53. Kuang S, Kuroda K, Le Grand F, Rudnicki MA. 2007 Asymmetric self-renewal and commitment of satellite stem cells in muscle. *Cell*. Jun 01;129(5):999-1010. DOI: 10.1016/j.cell.2007.03.044
54. Hughes CS, Postovit LM, Lajoie GA. 2010 Matrigel: a complex protein mixture required for optimal growth of cell culture. *Proteomics*. May;10(9):1886-90. DOI: 10.1002/pmic.200900758
55. Darabi R, Arpke RW, Irion S, Dimos JT, Grskovic M, Kyba M, Perlingeiro RC. 2012 Human ES- and iPS-derived myogenic progenitors restore DYSTROPHIN

and improve contractility upon transplantation in dystrophic mice. *Cell Stem Cell*. May 4;10(5):610-9. doi: 10.1016/j.stem.2012.02.015.

56. Lingjun Rao, Ying Qian, Alastair Khodabukus, Thomas Ribar & Nenad Bursac. 2018 Engineering human pluripotent stem cells into a functional skeletal muscle tissue. *Nat Comms*. 9:126 doi:10.1038/s41467-017-02636-4

57. Szkolnicka D, Hay DC. 2016 Concise Review: Advances in Generating Hepatocytes from Pluripotent Stem Cells for Translational Medicine. *Stem Cells*. Jun;34(6):1421-6. DOI: 10.1002/stem.2368

58. Lucendo-Villarin B, Rashidi H, Cameron K, Hay DC. 2016 Pluripotent stem cell derived hepatocytes: using materials to define cellular differentiation and tissue engineering. *J Mater Chem B Mater Biol Med*. May 28;4(20):3433-42. DOI: 10.1039/c6tb00331a

59. Szkolnicka D, Zhou W, Lucendo-Villarin B, Hay DC. 2013 Pluripotent stem cell-derived hepatocytes: potential and challenges in pharmacology. *Annu Rev Pharmacol Toxicol*. 53:147-59. DOI: 10.1146/annurev-pharmtox-011112-140306

60. Szkolnicka D, Farnworth SL, Lucendo-Villarin B, Storck C, Zhou W, Iredale JP, Flint O, Hay DC. 2014 Accurate prediction of drug-induced liver injury using stem cell-derived populations. *Stem Cells Transl Med*. Feb;3(2):141-8. DOI: 10.5966/sctm.2013-0146

61. Hay DC, Pernagallo S, Diaz-Mochon JJ, Medine CN, Greenhough S, Hannoun Z, Schrader J, Black JR, Fletcher J, Dalgetty D, et al. 2011 Unbiased screening of polymer libraries to define novel substrates for functional hepatocytes with inducible drug metabolism. *Stem Cell Res*. Mar;6(2):92-102. DOI: 10.1016/j.scr.2010.12.002

62. Lucendo-Villarin B, Cameron K, Szkolnicka D, Travers P, Khan F, Walton JG, Iredale J, Bradley M, Hay DC. 2015 Stabilizing hepatocellular phenotype using optimized synthetic surfaces. *J Vis Exp*. Sep 26(91):51723. DOI: 10.3791/51723

63. Andrews PW, Ben-David U, Benvenisty N, Coffey P, Eggan K, Knowles BB, Nagy A, Pera M, Reubinooff B, Rugg-Gunn PJ, et al. 2016 Assessing the Safety of Human Pluripotent Stem Cells and Their Derivatives for Clinical Applications. *Stem Cell Reports*. Jul 11;9(1):1-4. DOI: 10.1016/j.stemcr.2017.05.029

64. Spits C, Mateizel I, Geens M, Mertzaniadou A, Staessen C, Vandeskelde Y, Van der Elst J, Liebaers I, Sermon K. 2008 Recurrent chromosomal abnormalities in human embryonic stem cells. *Nat Biotechnol*. Dec;26(12):1361-3. DOI: 10.1038/nbt.1510

65. Canham MA, Van Deusen A, Brison DR, De Sousa PA, Downie J, Devito L, Hewitt ZA, Ilic D, Kimber SJ, Moore HD, et al. 2015 The Molecular Karyotype of 25 Clinical-Grade Human Embryonic Stem Cell Lines. *Sci Rep*. Nov 26;5:17258. DOI: 10.1038/srep17258

66. Oh SK, Chen AK, Mok Y, Chen X, Lim UM, Chin A, Choo AB, Reuveny S. 2009 Long-term microcarrier suspension cultures of human embryonic stem cells. *Stem Cell Res*. May;2(3):219-30. DOI: 10.1016/j.scr.2009.02.005

67. Lam AT, Li J, Chen AK, Birch WR, Reuveny S, Oh SK. 2015 Improved Human Pluripotent Stem Cell Attachment and Spreading on Xeno-Free Laminin-521-Coated Microcarriers Results in Efficient Growth in Agitated Cultures. *Biores Open Access*. 4(1):242-57. DOI: 10.1089/biores.2015.0010

68. Streuli CH, Bailey N, Bissell MJ. 1991 Control of mammary epithelial differentiation: basement membrane induces tissue-specific gene expression in the absence of cell-cell interaction and morphological polarity. *J Cell Biol*. Dec;115(5):1383-95.

69. Inman JL, Bissell MJ. 2010 Apical polarity in three-dimensional culture systems: where to now? *J Biol.*9(1):2. DOI: 10.1186/jbiol213

For Review Only

FIGURE LEGENDS

Figure 1a-c. Laminins are abundant components of the BMs and have essential roles in structural organization. Via binding to cell-surface receptors, such as integrins, laminins are also key regulators of cell behaviour (a). The molecular structure of laminin isoforms is cross-shaped. The Greek letters indicate the specific chains. The α chains have five globular domains (LG1–5) at the C terminus. The short arms are composed of a globular laminin N-terminal domain (LN), globular laminin IV domain (L4), or laminin four domain (LF). Each of these domains is separated by rod-like regions formed by multiple laminin epidermal-growth-factor-like (LE) domains (b). The $\alpha 5$ -chain laminins are key cell adhesion proteins of the natural stem cell niche. It is naturally expressed and secreted by cells in the inner cell mass ICM of the embryo whereas the $\alpha 1$ -chain laminins are mostly expressed in the Reichert’s membrane which supports the outer extra-embryonic layer of trophoblasts (c).

Figure 2a-d. Human PSCs grow as homogenous monolayers on LN-521, exhibiting a high nuclear-to-cytoplasm ratio and prominent nucleoli. Due to the biologically relevant support from the matrix, hESC and hiPSC can be seeded as single cells on LN-521 without the need to use apoptosis inhibitors (e.g. ROCKi) for survival. Within 1 hour after seeding, the cells have attached and are evenly distributed across the surface (a, day 0). The cells show high motility on LN-521, migrate and form small colonies and start dividing (a, day 1). The colonies merge (a, day 3) into a homogenous monolayer without signs of spontaneous differentiation (a, day 4). LN-521 supports higher post-seeding survival (24 h) of single-cell dissociated hPSCs, compared to Matrigel (MG) and non-relevant laminin matrices (b). In addition, human PSCs proliferate faster on LN-521 compared to other feeder-free matrices

(EHS extract; Engelbreth-Holm-Swarm mouse sarcoma extract), with about 10-fold increase every 4 days (c). LN-521 even enables large-scale automated processes for robust hPSC expansion in bioreactors. The cells easily attach, spread evenly on the surface of the microcarriers and gives a 20-fold expansion within 4 days (d).

Figure 3a-f. Differentiation of hESCs on LN-111 towards DA cells results in more than 40-fold increase of transplantable DA progenitors at day 16 (a) and the human progenitors innervate the striatum, become tyrosine hydroxylase (TH⁺) neurons and contribute to complete behavioural recovery after transplantation into animals modelling PD (b; scale bar represents 1.5mm). LN-521 improves muscle cell proliferation and differentiation, giving larger myotubes, higher amounts of nuclei per myotube (express myosin heavy chain, MHC) and more consistent differentiation in long-term cultures (c; MHC in green) compared to cells on Matrigel (d; DAPI in blue). Human ESCs differentiated on LN-521 and LN-111 demonstrate efficient hepatocyte maturation with significant improvements in cell function⁴². The hepatocyte-like cells are highly organized on LN-521, express transporter protein MRP1 (e; green) and HNF4a (red), and a majority of the cells are albumin⁺ (f; green) Cell nuclei are visualized with DAPI (blue).




Figure 1a-c. Laminins are abundant components of the BMs and have essential roles in structural organization. Via binding to cell-surface receptors, such as integrins, laminins are also key regulators of cell behaviour (a). The molecular structure of laminin isoforms is cross-shaped. The Greek letters indicate the specific chains. The α chains have five globular domains (LG1–5) at the C terminus. The short arms are composed of a globular laminin N-terminal domain (LN), globular laminin IV domain (L4), or laminin four domain (LF). Each of these domains is separated by rod-like regions formed by multiple laminin epidermal-growth-factor-like (LE) domains (b). The $\alpha 5$ -chain laminins are key cell adhesion proteins of the natural stem cell niche. It is naturally expressed and secreted by cells in the inner cell mass ICM of the embryo whereas the $\alpha 1$ -chain laminins are mostly expressed in the Reichert's membrane which supports the outer extra-embryonic layer of trophoblasts (c).

108x96mm (300 x 300 DPI)




Figure 2a-d. Human PSCs grow as homogenous monolayers on LN-521, exhibiting a high nuclear-to-cytoplasm ratio and prominent nucleoli. Due to the biologically relevant support from the matrix, hESC and hiPSC can be seeded as single cells on LN-521 without the need to use apoptosis inhibitors (e.g. ROCKi) for survival. Within 1 hour after seeding, the cells have attached and are evenly distributed across the surface (a, day 0). The cells show high motility on LN-521, migrate and form small colonies and start dividing (a, day 1). The colonies merge (a, day 3) into a homogenous monolayer without signs of spontaneous differentiation (a, day 4). LN-521 supports higher post-seeding survival (24 h) of single-cell dissociated hPSCs, compared to Matrigel (MG) and non-relevant laminin matrices (b). In addition, human PSCs proliferate faster on LN-521 compared to other feeder-free matrices (EHS extract; Engelbreth-Holm-Swarm mouse sarcoma extract), with about 10-fold increase every 4 days (c). LN-521 even enables large-scale automated processes for robust hPSC expansion in bioreactors. The cells easily attach, spread evenly on the surface of the microcarriers and gives a 20-fold expansion within 4 days (d).

87x41mm (300 x 300 DPI)




Figure 3a-f. Differentiation of hESCs on LN-111 towards DA cells results in more than 40-fold increase of transplantable DA progenitors at day 16 (a) and the human progenitors innervate the striatum, become tyrosine hydroxylase (TH+) neurons and contribute to complete behavioural recovery after transplantation into animals modelling PD (b; scale bar represents 1.5mm). LN-521 improves muscle cell proliferation and differentiation, giving larger myotubes, higher amounts of nuclei per myotube (express myosin heavy chain, MHC) and more consistent differentiation in long-term cultures (c; MHC in green) compared to cells on Matrigel (d; DAPI in blue). Human ESCs differentiated on LN-521 and LN-111 demonstrate efficient hepatocyte maturation with significant improvements in cell function⁴². The hepatocyte-like cells are highly organized on LN-521, express transporter protein MRP1 (e; green) and HNF4a (red), and a majority of the cells are albumin+ (f; green) Cell nuclei are visualized with DAPI (blue).

103x57mm (300 x 300 DPI)